[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501526":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":29,"locations":39,"responsibleParty":54,"collaborators":33,"id":56,"slug":33,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":33,"enrollmentInfo":66,"targetDuration":33,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":42,"whyStopped":33,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BCLC B and C HCC patients","EXPERIMENTAL","For each participant, 30mL of blood will be collected at inclusion\u002Fbefore treatment initiation (baseline) and during standard of care follow-up.\n\nThe blood sample will be taken, in consultation or in outpatient clinic during a blood test for health purposes.",[13],"Biological: Liquid Biopsy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Liquid Biopsy","30mL blood sample:\n\n* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis\n* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),\n* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell).",[9],[21],"Blood sample",[23,26],{"name":24,"affiliation":5,"role":25},"Catherine Alix-Panabières, Ph.D.","STUDY_DIRECTOR",{"name":27,"affiliation":5,"role":28},"Thomas Bardol, M.D.","PRINCIPAL_INVESTIGATOR",[30,35],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","+33682882757",null,"t-bardol@chu-montpellier.fr",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Catherine Guillemare","+33467332304","c-guillemare@chu-montpellier.fr",[40],{"facility":41,"status":42,"city":43,"state":33,"zip":33,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"CHU Montpellier","RECRUITING","Montpellier","France",{"type":46,"coordinates":47},"Point",[48,49],3.87635,43.61093,{"lat":49,"lon":48},[52],{"name":53,"role":31,"phone":33,"phoneExt":33,"email":33},"Thomas BARDOL, M.D.",{"type":55,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100501526",false,"NCT05810402","Liver Cancer and Immunotherapy in the Liquid Biopsy Era","Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY","LILIPSY","Inclusion Criteria:\n\n* Patients of at least 18 years old,\n* Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,\n* The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,\n* Advanced HCC defined by BCLC stages B and C,\n* Patients with oral consent.\n\nExclusion Criteria:\n\n* Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)\n* No personal history of neoplasia in the previous 5 years\n* No personal history of systemic inflammatory diseases\n* No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)\n* No affiliation or non-beneficiary of a Social Security system;\n* Vulnerable persons according to article L1121-6 of the CSP ;\n* Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;\n* Pregnant or breastfeeding women according to article L1121-5 of the CSP.\n* Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)",true,"ALL","18 Years",{"count":67,"type":68},60,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.\n\nThe main questions it aims to answer are:\n\n* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency?\n* Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?\n\nParticipants blood will be collected at several time points.",[74,75,76,77,17],"Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Immune Checkpoint Inhibitor",[74,79,77,17,80],"BCLC Stage B and C","Precision Medicine","2025-07-07",{"date":83,"type":84},"2025-07-10","ACTUAL",{"date":86,"type":84},"2023-06-28",{"date":88,"type":68},"2027-05",{"name":5,"class":6},1]